Compare GSK Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs CADILA HEALTHCARE - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA CADILA HEALTHCARE GSK PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 51.5 33.8 152.1% View Chart
P/BV x 11.6 5.9 195.7% View Chart
Dividend Yield % 1.4 0.6 234.3%  

Financials

 GSK PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
CADILA HEALTHCARE
Mar-20
GSK PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs3,595352 1,020.4%   
Low Rs1,253207 606.8%   
Sales per share (Unadj.) Rs184.7139.2 132.6%  
Earnings per share (Unadj.) Rs26.311.8 223.5%  
Cash flow per share (Unadj.) Rs29.218.6 157.1%  
Dividends per share (Unadj.) Rs20.003.50 571.4%  
Dividend yield (eoy) %0.81.3 65.9%  
Book value per share (Unadj.) Rs126.3101.4 124.6%  
Shares outstanding (eoy) m169.401,023.74 16.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.12.0 654.1%   
Avg P/E ratio x92.223.7 388.2%  
P/CF ratio (eoy) x83.115.0 552.4%  
Price / Book Value ratio x19.22.8 696.1%  
Dividend payout %76.129.8 255.7%   
Avg Mkt Cap Rs m410,626286,033 143.6%   
No. of employees `0005.013.4 37.0%   
Total wages/salary Rs m5,37224,145 22.2%   
Avg. sales/employee Rs Th6,306.710,632.7 59.3%   
Avg. wages/employee Rs Th1,083.11,801.2 60.1%   
Avg. net profit/employee Rs Th898.0898.5 99.9%   
INCOME DATA
Net Sales Rs m31,281142,531 21.9%  
Other income Rs m1,0231,139 89.8%   
Total revenues Rs m32,304143,670 22.5%   
Gross profit Rs m6,00924,198 24.8%  
Depreciation Rs m4866,965 7.0%   
Interest Rs m63,418 0.2%   
Profit before tax Rs m6,54014,954 43.7%   
Minority Interest Rs m0288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2870-   
Tax Rs m2,3733,198 74.2%   
Profit after tax Rs m4,45412,044 37.0%  
Gross profit margin %19.217.0 113.1%  
Effective tax rate %36.321.4 169.7%   
Net profit margin %14.28.5 168.5%  
BALANCE SHEET DATA
Current assets Rs m20,06187,154 23.0%   
Current liabilities Rs m14,54382,694 17.6%   
Net working cap to sales %17.63.1 563.7%  
Current ratio x1.41.1 130.9%  
Inventory Days Days5771 79.5%  
Debtors Days Days1494 15.0%  
Net fixed assets Rs m14,343133,236 10.8%   
Share capital Rs m1,6941,024 165.4%   
"Free" reserves Rs m19,704102,733 19.2%   
Net worth Rs m21,398103,757 20.6%   
Long term debt Rs m232,146 0.0%   
Total assets Rs m39,113236,866 16.5%  
Interest coverage x1,091.05.4 20,297.4%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.80.6 132.9%   
Return on assets %11.46.5 174.7%  
Return on equity %20.811.6 179.3%  
Return on capital %31.913.7 232.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53452,752 1.0%   
Fx outflow Rs m7,09114,504 48.9%   
Net fx Rs m-6,55738,248 -17.1%   
CASH FLOW
From Operations Rs m3,99425,054 15.9%  
From Investments Rs m-1,433-10,123 14.2%  
From Financial Activity Rs m-3,584-10,942 32.8%  
Net Cashflow Rs m-1,0233,989 -25.7%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 8.3 122.9%  
FIIs % 23.8 5.9 403.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 11.0 140.0%  
Shareholders   102,036 44,069 231.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   NATCO PHARMA  FRESENIUS KABI ONCO.  FDC  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

RBI's Relief Measures Amid Covid, 5G Trials by Mobile Operators, and Buzzing Stocks Today(Pre-Open)

Indian share markets witnessed positive trading activity throughout the day yesterday and ended higher.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider(Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


May 5, 2021 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS